Cardinal Health, Inc. vs Dell Technologies Inc.: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and Dell Technologies Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating Dell Technologies Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and Dell Technologies Inc. is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against $113.5B for Dell Technologies Inc., while their respective market capitalizations stand at $56.0B and $360.0B. Both Cardinal Health, Inc. and Dell Technologies Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Dell Technologies Inc.: Dell Technologies is one of the largest IT hardware companies in the world and, by 2026, one of the leading OEM suppliers of AI servers. It sells the laptops and desktops used by most large corporations and the servers, storage and networking that run their data centers. Founded by Michael Dell in 1984, taken private in 2013, combined with EMC in 2016 and relisted in 2018, it is now a fast-growing AI infrastructure company with a market value of roughly $360 billion in late September 2026.

Cardinal Health, Inc. and Dell Technologies Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and Dell Technologies Inc..

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

Dell Technologies Inc. business model: Dell makes money by selling hardware plus attached services and financing. The Infrastructure Solutions Group sells AI-optimized servers built around Nvidia (and some AMD) accelerators, traditional PowerEdge servers, networking and storage to enterprises, cloud service providers and governments; in Q2 fiscal 2027 ISG produced $31.8 billion of revenue and $4.8 billion of operating income. The Client Solutions Group sells commercial and consumer PCs, workstations and displays; Q2 fiscal 2027 CSG revenue was $15.0 billion, 88% of it commercial. Dell sells directly through its own sales force and dell.com and through channel partners, and adds recurring revenue from ProSupport warranties, deployment services, APEX subscriptions and Dell Financial Services leasing. AI servers carry thinner margins than storage or traditional servers, so Dell's profit growth depends on volume, configure-to-order supply chain efficiency and attaching higher-margin storage, networking and services.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of Dell Technologies Inc..

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Dell Technologies Inc. competitive advantage: Dell's edge is breadth and scale in enterprise relationships. It can sell a customer everything from 10,000 laptops to a liquid-cooled GPU cluster with storage, networking, deployment and financing under one contract, and support it worldwide. Its configure-to-order supply chain, purchasing power with Nvidia, Intel, AMD and memory suppliers, and the 'Dell AI Factory with NVIDIA' reference designs let it ship large AI racks quickly; Dell said it had more than 4,000 AI customers by early 2026. Long-standing ownership of the commercial PC installed base also gives it a natural channel to sell AI PCs and infrastructure to the same IT buyers.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and Dell Technologies Inc. each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

Dell Technologies Inc. growth strategy: Dell's growth strategy has three parts. First, win AI infrastructure share by shipping GPU-dense, liquid-cooled rack systems (PowerEdge XE servers with Nvidia Blackwell-generation GPUs) to neoclouds, sovereign AI programs and large enterprises, packaged as the Dell AI Factory. Second, attach higher-margin storage (PowerScale, PowerStore, Dell's private-cloud and data-lakehouse software), networking and services to those deals. Third, capture the commercial PC refresh with the simplified Dell, Dell Pro and Dell Pro Max brands introduced in 2025 and AI PCs. Capital returns through dividends and buybacks remain part of the equity story.

A closer look at the financial trajectory of Cardinal Health, Inc. and Dell Technologies Inc. rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

Dell Technologies Inc.: Dell's fiscal year ends in late January or early February. Revenue fell from $102.3 billion in fiscal 2023 to $88.4 billion in fiscal 2024 as post-pandemic PC demand faded, then recovered to $95.6 billion in fiscal 2025 and a record $113.5 billion in fiscal 2026, when net income reached $5.94 billion, operating cash flow topped $11 billion and $7.5 billion was returned to shareholders. Fiscal 2027 has accelerated: Q1 revenue was $43.8 billion (up 88%) and Q2 revenue was $47.0 billion (up 58%), with Q2 diluted EPS of $6.34. In September 2026 Dell raised full-year fiscal 2027 guidance to about $192 billion in revenue and $25.50 in non-GAAP EPS. The balance sheet still carries debt from the 2016 EMC deal, though leverage has fallen through the VMware spin-off and cash generation.